https://www.zaobao.com.sg/realtime/world/story20210506-1144682
美國莫德納公司周三(5月5日)宣布,一項小型臨床試驗的初步數據顯示,莫德納追加劑可改善人們對主要冠病變種病毒的免疫反應。
莫德納總裁邦塞爾(Stephane Bancel)說:“我們對這些新數據感到鼓舞,我們的追加劑策略應該能夠防禦這些新發現的變種,對此我們充滿信心。”
在臨床試驗中,40名參與者在接種兩劑疫苗後的六至八個月接受了中和抗體水平的測試。參與者之後接種了第三劑莫德納疫苗,或用於對抗特定變種病毒的追加劑,結果發現這兩種疫苗提高了對南非和巴西變種病毒的抗體水平。
PS
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two variants of concern (B.1.351, P.1) in previously vaccinated clinical trial participants
Booster dose of mRNA-1273.351, a strain-matched candidate, achieved higher titers against B.1.351 than a booster dose of mRNA-1273
mRNA-1273.351 and mRNA-1273 booster doses were generally well tolerated
Evaluation of a multivalent vaccine booster candidate, mRNA-1273.211, is ongoing; data expected shortly